Adriamycin Pfs

Sezary Syndrome, Acute Lymphoblastic Leukemia, Urinary Bladder Neoplasms + 20 more
Treatment
2 FDA approvals
20 Active Studies for Adriamycin Pfs

What is Adriamycin Pfs

DoxorubicinThe Generic name of this drug
Treatment SummaryDoxorubicin is an antibiotic used to treat cancer. It comes from a type of bacteria called Streptomyces peucetius var. caesius. The drug works by binding to the DNA of cancer cells and preventing them from growing and spreading.
Doxorubicin Hydrochlorideis the brand name
image of different drug pills on a surface
Adriamycin Pfs Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Doxorubicin Hydrochloride
Doxorubicin
1987
117

Approved as Treatment by the FDA

Doxorubicin, otherwise known as Doxorubicin Hydrochloride, is approved by the FDA for 2 uses which include Multiple Myeloma and Multiple Myeloma (MM) .
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Bortezomib
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Bortezomib

Effectiveness

How Adriamycin Pfs Affects PatientsDoxorubicin is a medication used to treat different types of cancer. It works by interfering with the DNA of cancer cells and stopping them from growing. It is often used to treat solid tumors, while other forms of the drug are used to treat leukemia. Doxorubicin can also stop the activity of certain enzymes, affect gene expression, and cause damage to DNA. This drug is not specific to any stage of the cell cycle, so it affects all cancer cells.
How Adriamycin Pfs works in the bodyDoxorubicin works by blocking the activity of an enzyme called topoisomerase II. It also forms a complex with DNA, preventing cells from reproducing. These two mechanisms work together to stop the spread of cancer cells.

When to interrupt dosage

The prescribed measure of Adriamycin Pfs is dependent upon the diagnosed condition, such as Malignant Lymphomas, Neoplasms and Sezary Syndrome. The dosage is contingent upon the mode of administration (e.g. Injectable, liposomal or Injection, solution) featured in the table below.
Condition
Dosage
Administration
Acute Lymphoblastic Leukemia
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Hodgkin's Lymphoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Sarcoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Endometrial Neoplasms
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Neoplasm Metastasis
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Waldenstrom Macroglobulinemia
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Sezary Syndrome
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
advanced uterine sarcoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
advanced Thymoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Neoplasms
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Stomach Neoplasms
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Carcinoma, Bronchogenic
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Metastatic Breast Cancer
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Thyroid Neoplasms
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
leukemia
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Acquired Immunodeficiency Syndrome
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Multiple Myeloma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Soft Tissue Sarcoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Lymphoma, Non-Hodgkin
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Mycosis Fungoides
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Warnings

Adriamycin Pfs has four contraindications and should not be taken while experiencing any of the ailments listed in the subsequent table.Adriamycin Pfs Contraindications
Condition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
severe persistent drug-induced myelosuppression
Do Not Combine
Heart Failure
Do Not Combine
Myocardial Infarction
Do Not Combine
There are 20 known major drug interactions with Adriamycin Pfs.
Common Adriamycin Pfs Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Doxorubicin.
Abetimus
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Acteoside.
Adriamycin Pfs Toxicity & Overdose RiskThe toxic dose of this drug in rats has been found to be 21800 micrograms per kilogram when administered subcutaneously.
image of a doctor in a lab doing drug, clinical research

Adriamycin Pfs Novel Uses: Which Conditions Have a Clinical Trial Featuring Adriamycin Pfs?

287 active trials are currently being conducted to explore the efficacy of Adriamycin Pfs in the management of advanced Soft Tissue Sarcoma (STS), Mycosis Fungoides (MF) and advanced Uterine Sarcoma.
Condition
Clinical Trials
Trial Phases
Lymphoma, Non-Hodgkin
1 Actively Recruiting
Phase 1
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Sezary Syndrome
9 Actively Recruiting
Phase 2, Phase 1
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Acute Lymphoblastic Leukemia
120 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Waldenstrom Macroglobulinemia
8 Actively Recruiting
Phase 2, Phase 1
advanced uterine sarcoma
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
0 Actively Recruiting
Carcinoma, Bronchogenic
0 Actively Recruiting
Thyroid Neoplasms
0 Actively Recruiting
Mycosis Fungoides
0 Actively Recruiting
advanced Thymoma
0 Actively Recruiting
Endometrial Neoplasms
0 Actively Recruiting
Neoplasms
0 Actively Recruiting
Sarcoma, Bone
8 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1
Urinary Bladder Neoplasms
22 Actively Recruiting
Phase 1, Phase 2, Phase 3
Neuroblastoma
0 Actively Recruiting
Soft Tissue Sarcoma
51 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3
Hodgkin's Lymphoma
63 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Sarcoma
6 Actively Recruiting
Phase 1, Phase 2

Adriamycin Pfs Reviews: What are patients saying about Adriamycin Pfs?

4.3Patient Review
11/18/2011
Adriamycin Pfs for Liver Cancer
I found this treatment to be effective and easy to use. All in all, I'm quite satisfied with my experience.
1.7Patient Review
1/1/2014
Adriamycin Pfs for Breast Cancer that has Spread to Another Part of the Body
I really dislike this medication. After just two treatments, my neutrophil counts were low, and after the third treatment (with a two week break in between to recover), they were even lower. I also had low hemoglobin counts, which forced me to receive a blood transfusion. I feel nauseated and have more pain in my spine since being on this medication, and I don't know if it's helping or not.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adriamycin pfs

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Adriamycin?

"nausea and vomiting, diarrhea, loss of appetite, missed menstrual periods, darkening of your skin or nails, weakness, tiredness, and eye redness."

Answered by AI

What is Adriamycin used to treat?

"Adriamycin is a medication used to treat various types of cancers, including breast cancer, bladder cancer, ovarian cancer, and thyroid cancer. It is also used to treat Hodgkin lymphoma, non-Hodgkin lymphoma, and certain types of leukemia."

Answered by AI

What does Adriamycin do to cancer?

"Adriamycin is a cancer medicine that belongs to a class of drugs called anthracyclines. It works by damaging the DNA inside cancer cells, which prevents them from replicating. Adriamycin works at any point in the cell cycle."

Answered by AI

What kind of chemo is Adriamycin?

"Some health care professionals may use the trade names Adriamycin or Rubex instead of the generic drug name Doxorubicin when referring to it. Doxorubicin is an anti-cancer chemotherapy drug, also known as an antineoplastic or cytotoxic drug."

Answered by AI

Clinical Trials for Adriamycin Pfs

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of St. Jude Children's Research Hospital in Memphis, United States.

High Intensity Interval Training for Hodgkin's Lymphoma Survivors

10 - 25
All Sexes
Memphis, TN
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated. Primary Objective: To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Feasibility will be assessed by: * Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Waitlist Available
Has No Placebo
St. Jude Children's Research HospitalAmy Berkman, MD
Image of Carolina Biooncology in Huntersville, United States.

RNDO-564 + Pembrolizumab for Bladder Cancer

18+
All Sexes
Huntersville, NC
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.
Phase 1
Recruiting
Carolina Biooncology (+1 Sites)Thomas Manley, MDRondo Therapeutics
Have you considered Adriamycin Pfs clinical trials? We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.Go to Trials
Image of Memorial Sloane Kettering Cancer Center in New York, United States.

Actinium Therapy for Soft Tissue Sarcoma

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years
Phase 1
Recruiting
Memorial Sloane Kettering Cancer CenterRatio Therapeutics, Inc.
Have you considered Adriamycin Pfs clinical trials? We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.Go to Trials
Image of UHN- Princess Margaret Cancer Center in Toronto, Canada.

BOLD-100 + Doxorubicin for Cancer

18+
All Sexes
Toronto, Canada
A Phase 1b, non-randomized, single-institution trial designed to assess the safety, tolerability and the highest dose with acceptable toxicity (RP2D) of BOLD-100 in combination with doxorubicin in patients diagnosed with advanced soft tissue sarcomas. The trial is divided into two phases: an initial dose-escalation phase for BOLD-100, followed by a dose-expansion phase based on the recommended dose for Phase 2. In the dose-escalation phase, we plan to enroll 12-15 patients, with an additional 17 patients in the dose-expansion phase. Participants will receive BOLD-100 intravenously on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin (75 mg/m², intravenous) administered on Day 1 of each 21-day cycle for up to six cycles. Participants will continue to receive BOLD-100 for as long as the cancer is not getting worse, The maximum cycles of doxorubicin are 6 cycles. Participants will undergo a screening assessment prior to the start treatment to determine eligibility for enrollment. Treatment will commence on Day 1 and will continue until the protocol-defined criteria for treatment withdrawal are met. Disease response will be assessed using CT or MRI scans, starting at 12 weeks after the initiation of treatment and continuing every 12 weeks until withdrawal. Upon treatment discontinuation or study withdrawal, a post-treatment assessment will be conducted at end of treatment and at 30 days of the last BOLD-100 dose, with follow-up visits scheduled every 3 months thereafter.
Phase 1
Waitlist Available
UHN- Princess Margaret Cancer Center
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Have you considered Adriamycin Pfs clinical trials? We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security